Skip to main content

Tesamorelin Peptide: Benefits, side effects, dosage details, and how it works

We dive deep into the research to see how tesamorelin may reduce visceral fat and help you achieve other health goals.

by
Last updated: Mar 21st, 2025
Peptide Upper Tesamorelian

Photo by Innerbody Research

You’ve probably encountered at least one prescription peptide ad without realizing it’s a peptide ad or even what a peptide is. But chances are that you recognize the names Ozempic, Wegovy, and even insulin. They’re all peptides.

Tesamorelin is also a peptide, but it belongs to a different class and has the potential to treat a host of concerns. Let’s take some time to learn what this powerful therapy can do to improve your health and quality of life.

Jump to

Jump to:

Why you should trust us

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

Everything we write is grounded in the available science on the subject. With tesamorelin and peptide therapies more broadly, we’ve spent over 200 hours digging in the literature and analyzing the findings to explore its promise as a valid treatment. As much as possible, we focused on direct clinical research on tesamorelin’s effects on visceral fat, muscle development, and cognition. When direct research was lacking, we examined the relevant biomechanisms — growth hormone, IGF-1 — to understand how increases in their production could affect human health and wellness. Our relationships with medical providers gave us a deeper understanding of the protocols and effects of tesamorelin based on their observations across years of practice, and we’ve folded that insight into this article to balance theory and real-world outcomes. One of our team members has also gained hands-on experience with tesamorelin in his ongoing peptide therapy.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

What is tesamorelin?

Tesamorelin (a.k.a. tesamorelin acetate or TH9507) is a synthetic, therapeutic polypeptide analog. Let’s break down what that means.

  • Synthetic: It was created in a laboratory.
  • Therapeutic: It’s used to treat disease.
  • Polypeptide: It’s a long chain of amino acids — 44, to be exact.
  • Analog: It’s based on a naturally occurring peptide — in this case, growth hormone-releasing hormone (GHRH).

Therapeutic peptides generally work by binding to cellular surfaces and triggering effects within the cells. According to the authors of a 2022 review on the subject, the mode of action is “similar … to biologics.” In other words, they mimic the native chemicals on which they’re based.

GHRH, the chemical basis for tesamorelin, does what its name says. Produced in the hypothalamus, the brain’s control center for many bodily functions, it causes the pituitary gland to release growth hormone. Growth hormone, in turn, acts on almost every organ and tissue in two aspects:

Physical growth

Growth hormone signals the cells in your cartilage and bones to ramp up their replication, especially during adolescence. Your whole body grows as a result. It’s what causes pubescent teens to grow taller and more muscular. Once the growth plates fuse and you can no longer gain height, growth hormone helps maintain your body’s established structure.

Metabolism

Just as GHRH stimulates the release of growth hormone, growth hormone increases the production of insulin-like growth factor-1 (IGF-1). In addition to promoting your physical growth, IGF-1 helps regulate your body composition. Specifically, low IGF-1 levels may lead to excessive body fat.

Like most therapeutic peptides, tesamorelin comes as a powder that must be reconstituted into a solution. The exact instructions for reconstitution may vary, but they generally involve combining the powder with sterile water in a syringe.

Peptides are normally administered by subcutaneous injection, and so it goes with tesamorelin. It has a dosing frequency of 5-7 days per week. The monthly protocol may involve a cycle of regular dosing for 2-3 months straight, followed by a one-month break.

You might sometimes find tesamorelin as an oral medication (e.g., tablets or troches), but availability seems to fluctuate. In most cases, it’s an injectable.

Also, peptide therapy is usually an ongoing treatment. With tesamorelin, you see results only as long as you continue your injections.

Current therapeutic uses for tesamorelin

Because it acts on growth and metabolism, tesamorelin’s therapeutic uses apply most directly to building physical strength and shrinking visceral fat.

Abdominal obesity

In a 12-month clinical trial published in 2010, which involved 404 HIV-infected patients with excess abdominal fat, the group that received 2mg of tesamorelin per day saw an 18% decrease in visceral fat compared to placebo.

There are two things to note in order to appreciate the full scope of these findings:

  • Visceral fat (i.e., fat accumulation around the abdominal organs) is famously stubborn and can’t be burned selectively through exercise. This is the type of fat that contributes most severely to things like diabetes, heart disease, and stroke. Yet tesamorelin appears to target it specifically. The researchers behind the 2010 trial theorized its mechanism of action involves “some mild aggravation of insulin,” high amounts of which correspond with visceral fat accumulation.
  • HIV and certain HIV treatments seem to facilitate the accumulation of visceral fat. It isn’t clear why. In any case, people with HIV are among the best-studied subjects for tesamorelin’s efficacy for fat loss.

Here, you can see, we’re talking about a hard-to-lose type of fat and mysterious circumstances of onset, but tesamorelin seems to work nonetheless. And although research on people without HIV is minimal to nonexistent at this time, researchers believe tesamorelin can yield similar outcomes in non-HIV populations.

But if you’re thinking it’s an alternative to a weight loss therapy like Ozempic, you should know that tesamorelin has demonstrated no effect on subcutaneous fat — the fat that most people associate with overweight and obesity. Moreover, visceral fat is likely to return in anyone who discontinues their tesamorelin therapy, whereas patients who’ve taken semaglutide (e.g., Ozempic) have seen at least some longer-lasting health outcomes after ending their treatment.

Therefore, there are three takeaways about tesamorelin and abdominal fat:

  1. Tesamorelin may be able to reduce your morbidity for serious chronic health conditions.
  2. This peptide probably isn’t the treatment you want for cosmetic weight loss.
  3. If you start tesamorelin therapy, you should expect to make it an ongoing commitment.

Muscle wasting, poor muscle tone, and weakness

As a therapy for people with HIV, tesamorelin plays double duty as a countermeasure against another common symptom of the disease: wasting. Defined in part as the loss of more than 10% of a person’s body weight, HIV-associated wasting is thought to stem from various aspects of HIV infection and treatment — low appetite, altered metabolism, poor nutrient absorption, opportunistic infections, depression, drug side effects, and inflammation. It’s a serious consequence but one that can be mitigated.

Tesamorelin can help with mitigation because it stimulates growth hormone secretion. Its utility toward this end was the subject of a 2020 analysis of two clinical trials on individuals with HIV in which the authors concluded, “Tesamorelin was effective in increasing skeletal muscle area and density.”

Strength and muscle studies are lacking with regard to non-HIV subjects, but the theoretical efficacy is there. Consider a 2006 study on Japanese patients with growth hormone deficiency, in which growth hormone replacement therapy resulted in “significantly improved body composition.”

Tesamorelin benefits

As you might expect, given its most common therapeutic uses, tesamorelin imparts noticeable benefits in terms of lipid profiles and muscle mass. Studies have demonstrated not only visceral fat loss, increased skeletal muscle, and improved body composition, but also elevated secretions of growth hormone and IGF-1.

But when the body experiences changes in one area of function, it can have a cascading effect on other areas as well. That’s why tesamorelin may provide additional benefits in:

Cognitive function

Tesamorelin’s mechanism of action follows quite cleanly to enhanced cognitive function. It stimulates growth hormone secretion, which then stimulates IGF-1 production, and both growth hormone and IGF-1 are linked to cognitive health. Case in point: a 2013 review supported growth hormone therapy as a treatment for patients with cognitive impairment, theorizing that growth hormone may interact with receptors in the central nervous system associated with learning and memory. Another case in point: a 2018 review found that IGF-1 plays a “major role” in adult brain function and decreases with age, a decrease that seems to precede cognitive decline in the elderly.

To tie this all together, we can point to a 2012 clinical trial directly examining the effects of tesamorelin on cognitive function. The subjects received either 1mg of tesamorelin or placebo over 20 weeks and were subsequently measured on their executive function, verbal memory, and visual memory. The outcome: tesamorelin demonstrated “favorable effects on cognition in both adults with [mild cognitive impairment] and healthy older adults.” Although adverse events were reported in 68% of tesamorelin subjects, the events themselves were mild — primarily localized skin reactions and increased joint pain.

Cardiovascular health

By shrinking visceral fat, tesamorelin effectively reduces a major cardiovascular risk factor. There’s even a recent paper examining the direct relationship between tesamorelin and cardiovascular disease. Published in 2025, the study concluded that tesamorelin can lead to a “significant reduction” in such risk among people with HIV, a population whose likelihood of a cardiovascular event is twice as high compared to the general population.

Skin health

While you won’t find any direct clinical studies on tesamorelin and skin health, there are several publications discussing the relationship between growth hormone, IGF-1, and skin-related health concerns. A good example is a review published in 2003 in Endocrine Reviews, in which the authors note the “importance of [growth hormone] and IGF systems in normal skin homeostasis.” They specifically mention the role that growth hormone plays in collagen synthesis and the effect that IGF has on skin cell proliferation. Hence, both are crucial for the “maintenance of epidermal integrity.”

In addition, according to the medical providers who’ve shared their observations with us, patients on tesamorelin may also see improvements in energy, physical strength, metabolism, hormonal balance, and markers of nonalcoholic fatty liver disease.

Is tesamorelin safe to use?

Tesamorelin generally has a low safety risk partly because it’s a prescription-only treatment. Prescribing physicians usually require initial and ongoing biomarker testing to ensure a candidate’s suitability.

The existing literature also indicates that tesamorelin is largely safe for use among people with indicated health concerns, such as excessive abdominal fat and muscle wasting. For example, in a study we referenced earlier, which entailed 52 weeks of tesamorelin administration in patients with HIV, the researchers found the peptide to be “generally well tolerated.” Importantly, tesamorelin caused no significant elevations in glucose, which would have represented a severe safety hazard given the relationship between hyperglycemia and diabetes.

That being said, there are contraindications and potential side effects:

Contraindications with tesamorelin

Current research has yet to establish the safety of tesamorelin among women who are pregnant or breastfeeding. Also, its growth hormone-stimulating properties make it unsafe for people with active cancer, and its action on the pituitary gland means it’s unsuitable for people with a pituitary gland disorder.

Side effects of tesamorelin

Like many injectable treatments, tesamorelin can cause injection site reactions (redness, swelling, mild discomfort) as well as joint and muscle pain. In some cases, users may experience mild flu-like symptoms — fatigue, headache, nausea — especially at the onset of treatment. More severe side effects are possible, including but not limited to a high fever, blistering at the injection site, and allergic symptoms such as itching, rash, hives, and vomiting. If you experience a severe side effect, you should immediately seek medical attention.

Research-grade vs. pharmaceutical-grade tesamorelin

When you’re shopping for tesamorelin online, you might come across options listed as “research-grade,” “laboratory-grade,” or “reagent-grade.” That means the tesamorelin is intended for laboratory use only — so that trained professionals can study its structure and effects. It has not been stringently monitored for contaminants that can harm the user, so it is potentially unsafe and not to be used as a therapeutic drug.

What you should look for is something labeled “pharmaceutical-grade” or “GMP API” (good manufacturing practices for active pharmaceutical ingredients). Tesamorelin labeled as such has been approved by the Food & Drug Administration for human use.

What’s it like to use tesamorelin?

The tesamorelin experience can vary to certain degrees, but new patients can expect some commonalities in terms of the treatment protocol. Here, we take you through its various aspects:

Biomarker testing

If you’re a candidate for tesamorelin, your doctor will order lab tests to analyze biomarkers related to pertinent health conditions. Biomarker testing will also take place periodically throughout your treatment so that your doctor can assess your response to the medicine.

Dosing and administration

A tesamorelin dose is usually 1-2mg by subcutaneous injection, the dosing frequency is either five or seven days a week, and each day’s dose normally occurs in the evening to coincide with the body’s natural growth hormone release pattern.

Each dose is self-administered. Your prescribing physician will likely give you a handout detailing the process, as well as a kit that includes a vial of tesamorelin powder, a vial of bacteriostatic water, alcohol swabs, and needle syringes.

You’ll be responsible for reconstituting the tesamorelin powder with the bacteriostatic water. To do so, you:

  • Sterilize the vials with an alcohol swab to prevent pathogenic transmission
  • Inject the needle syringe into the bacteriostatic water vial and draw out the amount indicated by your prescriber
  • Inject the water-filled syringe into the tesamorelin vial and slowly introduce the water to the powder
  • Remove the syringe
  • Gently swirl to dissolve the powder into a solution (don’t shake to mix, which can degrade the peptide and create foam)
  • Reinsert the syringe into the tesamorelin vial and draw out the prescribed volume of solution
  • Sterilize the injection site — an area of subcutaneous fat in the belly, thigh, or arm
  • Poke the syringe needle into the injection site and depress the plunger
  • Dispose of the used syringe

Tesamorelin often comes in a large vial meant to be used throughout the month, in which case reconstitution is necessary only once per shipment, not per dose. However, some tesamorelin comes in single-use vials, which require daily reconstitution.

Storage

As long as you aren’t using single-use vials, a shipment’s worth of tesamorelin should last four weeks. The remainder must be stored in the refrigerator, ideally between 36 and 46 degrees Fahrenheit (2-8 degrees Celsius). The other kit items — bacteriostatic water, alcohol swabs, and needle syringes — can be kept at room temperature. You shouldn’t have to worry about the medicine becoming contaminated while in storage. Medical vials often have self-healing rubber stoppers on top. The stoppers have elastic properties that allow them to “close” the puncture you make with the needle when you insert or draw out the contents. If your vials don’t have rubber stoppers, you’ll want to ask your prescriber about the ideal storage protocol.

Treatment cycle and timeline of effects

Treatment may follow a cycle. A normal cycle lasts 3-4 months — that’s 2-3 months on, followed by one month off. Treatment is ongoing, so a year comprises 3-4 cycles.

Therapeutic effects tend to follow a schedule, too. Based on what we’ve learned from our interactions with treatment providers, we’d say an ordinary tesamorelin treatment timeline looks like this:

  • Within 1-2 weeks, you should begin to experience reductions in your visceral fat.
  • At 4-6 weeks, your abdominal fat should begin to reduce significantly, and your lipid profiles ought to improve. Improvements in muscle mass are often seen at this point as well.
  • By 8-12 weeks, the full benefits of treatment should become evident: substantial visceral fat reduction, better body composition, and enhanced cognitive function.

Thereafter, it’s mostly about maintaining your protocol and health outcomes, but you should also start to see improvements in cardiovascular health along with positive changes in physical performance attendant with your changing body composition.

Who’s a candidate for tesamorelin?

Tesamorelin is approved as a therapy for patients with HIV who’ve accumulated excess abdominal fat, but it is also prescribed off-label to people seeking reductions in their visceral adiposity, increases in their muscle mass, and improvements in their cardiovascular or cognitive health. In some cases, treatment is indicated for individuals seeking cosmetic improvements in their skin health.

More specifically, you may be a candidate for tesamorelin if you (a) don’t have a contraindicated health condition and (b) are at risk of one or more of the following:

  • HIV-associated wasting or weakness
  • Fatigue
  • Overweight or obesity
  • Age-related muscle loss
  • Cognitive decline or memory loss
  • Poor focus
  • Atherosclerosis
  • High cholesterol
  • Cardiovascular disease
  • Nonalcoholic fatty liver disease
  • Skin aging or collagen loss

Where to find tesamorelin

Clinics have been prescribing peptides to private clients for years, and telehealth is only just catching up. Even among the reputable telehealth providers that are riding the peptide wave, the selection is usually limited to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. Tesamorelin, however, isn’t a GLP-1 RA and currently isn’t offered by many leading telehealth platforms such as Hims, Hers, Eden, Henry Meds, or Strut.

Right now, the best way to get a tesamorelin prescription is through a local medical provider.

Because the telehealth space is playing catch-up, less-reputable outfits have seen an opportunity to capitalize on the growing public interest in peptide therapy. That’s why you can still find a few online purveyors that carry tesamorelin, and it’s tough to say whether or not a given one is trustworthy.

Often, you’ll find that they sell research-grade tesamorelin, which is intended only for laboratory use. If you were to inject research-grade tesamorelin into your body, you run the risk of introducing contaminants that could cause serious harm. Legitimate online peptide purveyors will deal exclusively in products labeled “pharmaceutical-grade” or “GMP API,” which indicates FDA approval for human use.

However, among the few online providers that offer tesamorelin, none of them appear to be well-represented on the major consumer watchdog sites. They tend to have only a handful of reviews, and that’s hardly enough to feel confident about the honesty of their labeling or the quality of their products. Again, we’re not saying one or another operation is not legit, only that we can’t confidently make an accurate assessment at this time.

33

Sources

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. National Institute of Diabetes and Digestive and Kidney Diseases. (2018). Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

  2. Forbes, J., & Krishnamurthy, K. (2023). Biochemistry, peptide. StatPearls [Internet].

  3. Wang, L., et al. (2022). Therapeutic peptides: Current applications and future directions. Signal Transduction and Targeted Therapy, 7(1), 1-27.

  4. Cleveland Clinic. (2022). Hypothalamus. Cleveland Clinic.

  5. Utiger, R. D. (n.d.). Growth hormone-releasing hormone. Brittanica.

  6. Cleveland Clinic. (2022). Human growth hormone (HGH). Cleveland Clinic.

  7. Kubo, H., et al. (2022). Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects: A Japanese single-center, retrospective study. Scientific Reports, 12(1), 1-9.

  8. Rochira, V., & Guaraldi, G. (2017). Growth hormone deficiency and human immunodeficiency virus. Best Practice & Research Clinical Endocrinology & Metabolism, 31(1), 91-111.

  9. Falutz, J., et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. Journal of Acquired Immunodeficiency Syndromes, 53(3), 311-322.

  10. Cleveland Clinic. (2022). Visceral fat. Cleveland Clinic.

  11. Hardy, O. T., Czech, M. P., & Corvera, S. (2012). What causes the insulin resistance underlying obesity? Current Opinion in Endocrinology, Diabetes, and Obesity, 19(2), 81-87.

  12. HIVinfo. (2024). HIV and lipodystrophy. NIH.

  13. National Institutes of Health. (2019). Drug reverses signs of liver disease in people living with HIV. NIH.

  14. Dhillon, S. (2011). Tesamorelin: A review of its use in the management of HIV-associated lipodystrophy. Drugs, 71(8), 1071-1091.

  15. Siddiqui, J., et al (2021). HIV-associated wasting prevalence in the era of modern antiretroviral therapy. AIDS, 36(1), 127-135.

  16. International Association of Providers of AIDS Care. (2024). Wasting syndrome. AIPAC.

  17. Adrian, S., et al. (2019). The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3),154-159.

  18. Chihara, K., et al (2006). Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: A randomised, placebo-controlled study. Growth Hormone & IGF Research, 16(2), 132-142.

  19. Stanley, T. L., et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of Clinical Endocrinology and Metabolism, 96(1), 150-158.

  20. Nyberg, F., & Hallberg, M. (2013). Growth hormone and cognitive function. Nature Reviews Endocrinology, 9(6), 357-365.

  21. Frater, J., Lie, D., Bartlett, P., & McGrath, J. J. (2018). Insulin-like growth factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: A review. Ageing Research Reviews, 42, 14-27.

  22. Baker, L. D., et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: Results of a controlled trial. Archives of Neurology, 69(11), 1420-1429.

  23. Zheng, L., et al. (2023). Association between visceral obesity and 10-year risk of first atherosclerotic cardiovascular diseases events among American adults: National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine, 10, 1249401.

  24. Grinspoon, S. K., et al. (2025). Impact of tesamorelin on cardiovascular disease risk prediction scores in phase 3 studies treatment arms: Subanalysis. Open Forum Infectious Diseases, 12(Supplement 1).

  25. Edmondson, S. R., Thumiger, S. P., Werther, G. A., & Wraight, C. J. (2003). Epidermal homeostasis: The role of the growth hormone and insulin-like growth factor systems. Endocrine Reviews, 24(6), 737-764.

  26. Cleveland Clinic. (2023). Hyperglycemia (High blood sugar). Cleveland Clinic.

  27. Chae, W., Kim, H., & Kim, S. (2015). Growth hormone treatment and risk of malignancy. Korean Journal of Pediatrics, 58(2), 41-46.

  28. Cauter, E. V., & Plat, L. (1996). Physiology of growth hormone secretion during sleep. The Journal of Pediatrics, 128(5, pt. 2), S32-37.

  29. Youmshajekian, L. (2025). Most people stop Ozempic after two years. What happens to weight and health? Scientific American.

  30. Veterans Health Library. (n.d.). Tesamorelin injection. U.S. Department of Veterans Affairs.

  31. Cleveland Clinic. (n.d.). Tesamorelin injection. Cleveland Clinic.

  32. U.S. Food & Drug Administration. (2001). Q7A: Good manufacturing practice guidance for active pharmaceutical ingredients. FDA.

  33. Animal Care & Use Program. (n.d.). Pharmaceutical grade. University of Michigan.